As Alnylam Weighs Dropping AMD Candidate, Rivals Are Buoyed By Emerging Research Data | GenomeWeb

Alnylam was tight-lipped this week after CEO John Maraganore suggested that an increasingly competitive market might force the firm to abandon its AMD candidate.

But officials at Alnylam rival Acuity Pharmaceuticals remained upbeat about their VEGF-targeting drug, Cand5, after recent data showed that that the competing VEGF compound Lucentis, co-developed by Genentech and Novartis, may be an effective treatment for the condition.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.